Example: air traffic controller
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 11/2018 _____ FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Genitourinary Conditions 6 …
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION BOTOX
media.allergan.comSee full prescribing information for complete boxed warning. The effects of BOTOXand all botulinum toxin products may spread from ... BOTOX is indicated for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and older.
HIGHLIGHTS OF PRESCRIBING INFORMATION …
media.allergan.comrandomized, double-blind, placebo-controlled, Phase 3 trials in adult patients with migraine (Studies 1 and 2), a total of 1,439 patients received UBRELVY 50 mg or 100 mg [see Clinical Studies (14)]. Of the UBRELVY-treated patients in these 2 studies, approximately 89% were female, 82% were White, 15% were Black, and
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE …
media.allergan.comJun 26, 2019 · The safety and effectiveness of dosing with BOTOX Cosmetic more frequently than every 3 months have not been clinically evaluated. The safe and effective use of BOTOX Cosmetic depends upon proper storage of the product, selection of the correct dose, and proper reconstitution and administration techniques.
HIGHLIGHTS OF PRESCRIBING INFORMATION VRAYLAR ...
media.allergan.comReactions have ranged from rash, pruritus, urticaria, and events suggestive of angioedema (e.g., swollen tongue, lip swelling, face edema, pharyngeal edema, and swelling face). Page 5 of 38 5. WARNINGS AND PRECAUTIONS 5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These ... - …
media.allergan.commicronucleus test in mice and Chinese hamsters, the chromosome-aberration tests in Chinese hamster bone-marrow, the mouse dominant lethal assay, and the DNA-repair test in sperm from treated mice. A study analyzing sister chromatid exchange (SCE) induction by cyclosporine using human lymphocytes in vitro gave
Silicone-Filled Breast Implants and NATRELLE INSPIRA ...
media.allergan.comPage 1 INTRODUCTION Directions to the Physician The information supplied in this Directions for Use document is intended to provide physicians an overview of essential information about NATRELLE ® Silicone-Filled Breast Implants and NATRELLE INSPIRA® Breast Implants, including the indications for use, contraindications, warnings, precautions, important factors for …
ESTRACE® Cream (estradiol vaginal cream, USP, 0.01% ...
media.allergan.comFor those outcomes included in the WHI “global index” that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women- years in the group treated with CE plus MPA were 7 more CHD events, 8 more strokes, 10 more PEs, and 8 more invasive
NATRELLE Silicone-Filled Breast Implants and
media.allergan.comgel bleed (small quantities of gel diffusing from the implant shell) of silicone gel-filled implants may occur. I understand that if I have a saline-filled implant, my breast may deflate in appearance if there is a rupture or leakage of the saline. I understand that if I have a silicone gel-filled breast implant, I or
PRED FORTE (prednisolone acetate ophthalmic suspension ...
media.allergan.comJun 06, 2018 · infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing. The development of secondary ocular infection (bacterial, fungal, and viral) has occurred. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroids.
Armour® Thyroid (thyroid tablets, USP)
media.allergan.comwhere the integrity of the cardiovascular system, particularly the coronary arteries, is suspected. These include patients with angina pectoris or the elderly, in whom there is a greater likelihood of occult cardiac disease. In these patients, therapy should be initiated with low doses, i.e., 15-30 mg ®Armour Thyroid (thyroid tablets, USP).
Related documents
HIGHLIGHTS OF PRESCRIBING INFORMATION thereafter or …
docs.boehringer-ingelheim.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014 -----RECENT MAJOR CHANGES-----
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE …
seagendocs.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ADCETRIS safely and effectively. See full prescribing information for ADCETRIS. ADCETRIS® (brentuximab vedotin) for …
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.us.astellas.comHIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use MYRBETRIQ ® /MYRBETRIQ ® GRANULES safely and effectively. See full prescribing information for MYRBETRIQ /MYRBETRIQ GRANULES. o. not chew, divide. MYRBETRIQ (mirabegron extended-release tablets), for oral use
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
pp.jazzpharma.comSee Full Prescribing Information for complete dosing instructions (2.1-2.7). Dosage for Adult Patients with Narcolepsy • Initiate dosage at 4.5 g per night orally, divided into two doses (2.1). • Titrate to effect in increments of up to 1.5 g per night per week (2.1). • Recommended dosage range: 6 g to 9 g per night orally, divided into two
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.cimzia.comSee full prescribing information for complete boxed warning. o Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
www.xhance.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 04/2021 _____ FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE . 2 DOSAGE AND ADMINISTRATION . 2.1 Nasal Polyps . 2.2 Administration Information . 3 DOSAGE FORMS AND STRENGTHS . 4 CONTRAINDICATIONS . 5 …
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
labeling.bayerhealthcare.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-Approved Patient Labeling. Revised: 7/2020 _____ FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Hepatocellular Carcinoma 1.2 Renal Cell Carcinoma 1.3 Differentiated Thyroid Carcinoma 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
labeling.bayerhealthcare.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 7/2021 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1. Dosing Over Time 2.2. Insertion Instructions 2.3 Patient Follow-up 2.4 Removal of Kyleena 2.5 Continuation of Contraception after Removal